Late-breaking abstract: Preclinical evaluation of an inhibitor of cytosolic phospholipase A2 α for the treatment of asthma
C. Hewson, S. Patel, L. Calzetta, H. Campwala, S. Havard, E. Luscombe, P. Clarke, P. Peachell, M. Matera, M. Cazzola, C. Page, W. Abraham, C. Williams, J. Clark, N. Clarke, M. Yeadon (Sandwich, Sheffield, London, United Kingdom; Rome, Naples, Italy; Miami Beach, Cambridge, United States Of America)
Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Hewson, S. Patel, L. Calzetta, H. Campwala, S. Havard, E. Luscombe, P. Clarke, P. Peachell, M. Matera, M. Cazzola, C. Page, W. Abraham, C. Williams, J. Clark, N. Clarke, M. Yeadon (Sandwich, Sheffield, London, United Kingdom; Rome, Naples, Italy; Miami Beach, Cambridge, United States Of America). Late-breaking abstract: Preclinical evaluation of an inhibitor of cytosolic phospholipase A2 α for the treatment of asthma. Eur Respir J 2011; 38: Suppl. 55, 4498
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011
Safety and pharmacology of a soluble epoxide hydrolase inhibitor Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Late-breaking abstract: Pre-clinical efficacy of RP5090 in PI3Kδ mediated airway disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011
SPARTA: Efficacy and safety assessment of two regimens of alpha1 -proteinase inhibitor in emphysema due to alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Regulation and overexpression of 85-kDa cytosolic phospholipase A2 in asthma Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases Year: 2010
Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Association between cyclooxygenase inhibitor use and efficacy of immunotherapy: a retrospective study Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018
Late-breaking abstract: Genome-wide association of GLCCI1 with asthma steroid treatment response Source: Annual Congress 2011 - Phenotyping asthma: a clue for treatments? Year: 2011
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE) Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010
Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018
Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1 -proteinase inhibitor in alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013